Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: THC stock price vs CYH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CYH's multiple
Needs CYH P/E.
Implied fair value · at THC's multiple
Needs Annual EPS, THC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TENET HEALTHCARE CORP · implied price per share
Bear
$105.38
Base
$143.97
Bull
$194.22
COMMUNITY HEALTH SYSTEMS INC · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
CYH · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe THC can sustain its current margin profile and cash generation while the P/E-based implied valuation remains distorted by the input assumptions, then hold or add selectively because THC’s operating metrics are clearly stronger than CYH’s and leverage is more manageable than CYH’s.
On the provided P/E basis, THC’s current price of $196.49 sits far above the implied price of $13.19, which implies a -93.3% downside and makes the stock look extremely overvalued on that single metric. However, the broader valuation set is mixed: THC trades at 12.7x P/E and 5.0x EV/EBITDA versus CYH at 0.9x P/E and 5.3x EV/EBITDA, while THC’s current price is also near the top of its historical band.
Supporting Metrics
